Integrase · SINGLE PROTEIN · Human immunodeficiency virus 1
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Integrase shows clinical signal disease relevance led by HIV infection. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt T1QYY3. Start with HIV infection, then reuse UniProt T1QYY3 as the stable protein anchor across project notes and exports.
Start with HIV infection, then reuse UniProt T1QYY3 as the stable protein anchor across project notes and exports.
Integrase shows clinical signal disease relevance led by HIV infection. 1 linked drug remains visible in the same block.
Start review with HIV infection because it currently carries clinical signal support. Linked drugs include BMS-707035. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyGag-Pol polyprotein
Review this target as Integrase, mapped to UniProt T1QYY3. ChEMBL maps the protein component as Gag-Pol polyprotein. Sequence length is 288 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Integrase as ChEMBL target CHEMBL4296304, mapped to UniProt T1QYY3. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Integrase is the right protein anchor across sources, using UniProt T1QYY3 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why HIV infection is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Integrase |
| Target Type | SINGLE PROTEIN |
| Organism | Human immunodeficiency virus 1 |
| UniProt | T1QYY3 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Gag-Pol polyprotein |
| UniProt Accession | T1QYY3 |
| Component Type | Protein |
| Sequence Length | 288 aa |
Gag-Pol polyprotein
Review this target as Integrase, mapped to UniProt T1QYY3. ChEMBL maps the protein component as Gag-Pol polyprotein. Sequence length is 288 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Integrase shows clinical signal disease relevance led by HIV infection.
Start review with HIV infection because it currently carries clinical signal support. Linked drugs include BMS-707035. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3989866 | 8.51 | EC50 | 3.1 | Approved |
| CHEMBL4786078 | 8.1 | Ki | 8.0 | Preclinical |
| CHEMBL4779601 | 7.77 | Ki | 17.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 3 | 3 | 8.1 |